At Northwestern Medicine, we put our patients first in an effort to deliver the best cancer care. Our teams of experts are here to help support patients and their caregivers during all stages of their cancer journey: diagnosis, treatment, and recovery.
Northwestern Medicine’s cancer centers provide access to state-of-the art therapies and comprehensive cancer care offering leading-edge medical, surgical and radiation oncology treatment options, as well as access to specialized research, clinical trials and diagnostic services.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is proud to be ranked as one of the top 8 cancer programs in the country by U.S. News & World Report.
Overcoming CDK4/6 Inhibitor Resistance in ESR1-Mutant HR+/HER2- Breast Cancer
December 17th 2020Massimo Cristofanilli, MD, highlights the introduction of CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib, which has been a significant addition to the hormone receptor–positive, HER2-negative breast cancer armamentarium.
PROfound Trial With Olaparib Shows Feasibility of Personalizing Care in mCRPC
October 15th 2020Maha H.A. Hussain, MD, FACP, FASCO, discusses the updated findings from the PROfound trial, its clinical significance in the treatment of patients with mCRPC paradigm, and the promise of precision medicine.
PSA Responses to Enzalutamide Significantly Associated With Longer MFS in nmCRPC
October 1st 2020Maha H.A. Hussain, MD, FACP, FASCO, discusses the prognostic associations of depth of PSA responses with MFS in patients with nmCRPC and a rapidly rising PSA who have been treated with enzalutamide and other efforts being made in this disease.
Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer
July 13th 2020William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.
Maintenance Rituximab Improves Survival in Older Patients With MCL, But More Work Needed
June 16th 2020Reem Karmali, MD, discusses survival outcomes in older patients with MCL with maintenance rituximab and highlights other ongoing MCL research efforts to optimize maintenance strategies in this patient population.
Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
June 11th 2020In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.
Talking Tumors: Treating With Immunotherapy and Targeted Therapy in Lung Cancer
April 20th 2020Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.
Dr. Hussain on the Implications of the PROfound Trial in mCRPC
March 28th 2020Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).